Repotrectinib 40mg Capsules

Repotrectinib 40mg Capsules represent a next-generation advancement in the field of precision oncology, specifically designed as a tyrosine kinase inhibitor (TKI) targeting ROS1 and NTRK oncogenic fusions. Pharmacologically, repotrectinib is distinguished by its unique “macrocyclic” structure. Unlike earlier linear kinase inhibitors, repotrectinib is a compact, rigid molecule designed to fit precisely inside the ATP-binding pocket of the kinase, even when bulky resistance mutations are present.

One of the primary challenges in treating ROS1-positive or NTRK-positive cancers is the development of “solvent-front” mutations (such as ROS1 G2032R or TRKA G595R) that physically block earlier drugs (like crizotinib or entrectinib) from binding. Repotrectinib 40mg Capsules overcome this steric hindrance, effectively inhibiting both the wild-type fusions and these difficult-to-treat resistance mutations. This capability stops the downstream signaling pathways essential for tumor growth and survival, making it a potent option for patients who have exhausted other therapies.

Indications / Uses of Repotrectinib 40mg Capsules

Repotrectinib 40mg Capsules are indicated for the treatment of adult and pediatric patients (12 years of age and older) with specific genetically defined solid tumors. The primary FDA-approved indications include:

• ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Indicated for adult patients with locally advanced or metastatic NSCLC that is ROS1-positive. This includes patients who are TKI-naïve (no prior treatment) and those who have been previously treated with other ROS1 inhibitors.
• NTRK Gene Fusion-Positive Solid Tumors: Indicated for adult and pediatric patients (12 years and older) with solid tumors that have an NTRK gene fusion, are locally advanced or metastatic, and where surgical resection is likely to result in severe morbidity. This is a “tumor-agnostic” indication, meaning it applies to various cancer types (e.g., thyroid, colon, lung) provided the genetic marker is present.
• Dose Modification: The 40mg capsule strength is particularly utilized for dose reductions in patients who experience adverse reactions to the standard starting dose, or for specific weight-based dosing requirements in smaller patients.

Key Features

• Macrocyclic Design: Its rigid 3D structure allows it to bind effectively to the kinase target despite the presence of common resistance mutations that render other drugs ineffective.
• CNS Penetration: Repotrectinib 40mg Capsules are designed to cross the blood-brain barrier efficiently, providing intracranial activity to treat or prevent brain metastases, which are common in ROS1-positive lung cancer.
• Broad Efficacy: Clinical trials (TRIDENT-1) demonstrated durable responses in both TKI-naïve patients and those heavily pre-treated with other inhibitors.
• Oral Administration: The capsule formulation allows for convenient oral dosing.

Storage for Repotrectinib 40mg Capsules

To ensure the stability and therapeutic potency of Repotrectinib 40mg Capsules, proper storage is essential. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). Keep the capsules in their original bottle to protect them from moisture and light. Do not remove the desiccant if present. Store the container tightly closed in a dry, secure place, out of the reach and sight of children and pets.

Important Note on Repotrectinib 40mg Capsules

Therapy with Repotrectinib 40mg Capsules involves a unique “step-up” dosing regimen to mitigate side effects. Patients typically start at a lower frequency (once daily) for the first 14 days before increasing to twice daily. It is critical to follow this schedule strictly to reduce the risk of dizziness and ataxia (impaired coordination), which are among the most common neuro-cognitive adverse events associated with TRK inhibition. Patients should be advised to exercise caution when driving or operating machinery or to avoid these activities if they experience dizziness.

Other common side effects include dysgeusia (changes in taste), peripheral neuropathy (numbness/tingling), and constipation.

Repotrectinib can cause fetal harm; therefore, it is not recommended for pregnant women. Females of reproductive potential and males with female partners should use effective non-hormonal contraception during treatment and for a specified period after the final dose.

The drug interacts with CYP3A4 enzymes. Strong and moderate CYP3A4 inhibitors (e.g., grapefruit juice, ketoconazole) and inducers should be avoided or managed with dose modifications. Always review your full medication list with your oncologist before starting treatment.